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Introduction {#sec001}
============

Glioblastoma (GBM) is the most common central nervous system tumor in adults and the deadliest primary malignant brain tumor. Patients succumb to death shortly after diagnosis, despite multi-modal therapy. Surgical resection of the tumor followed by concurrent chemo-radiotherapy is the standard treatment nowadays, and management of GBM has advanced little in the last two decades. The overall 2-year survival of GBM following optimal treatment is only 27% \[[@pone.0233188.ref001], [@pone.0233188.ref002]\]. GBM typically occurs in a single brain lesion and tends to recur locally just adjacent to the original tumor site following resection and adjuvant radiotherapy. According to previous studies on the pattern of failure for GBM patients, more than 80% of tumor relapse occurred within the initial tumor margin \[[@pone.0233188.ref003]--[@pone.0233188.ref005]\]. Given the importance of local control, it is advised to achieve gross tumor resection (GTR) and administer an escalated radiation dose in order to avoid local tumor recurrence. An analysis of the National Cancer Database revealed that patients who received GTR did have an increased survival rate over patients who underwent subtotal resection or biopsy only \[[@pone.0233188.ref006]\]. However, completion of GTR would increase the risk of neurologic deficits.

In the era of conformal and precise radiation, several studies tried to administer an escalated radiation dose to the GBM tumor surgical bed or residuum to improve local control \[[@pone.0233188.ref005], [@pone.0233188.ref007]--[@pone.0233188.ref012]\]. Milano et al. investigated the pattern and timing of GBM treated by biopsy or resection followed by standard 60-Gy radiation and temozolomide (TMZ) therapy and found that 80% of recurrence still occurred in the primary tumor site \[[@pone.0233188.ref007]\]. Several previous studies administered an escalated radiation dose (\> 60 Gy), even up to 90 Gy) with the aim to achieve better local control \[[@pone.0233188.ref005], [@pone.0233188.ref008]--[@pone.0233188.ref010]\]. Most of them failed to prolong survival through an escalated dose. However, two recent reports showed a positive prognostic effect of a moderately integrated radiation boost dose (\> 60 Gy) with a superior local control, and this also translated to a better overall survival (OS) \[[@pone.0233188.ref011], [@pone.0233188.ref012]\].

Given the inconsistent clinical results, this study aimed to compare survival outcomes between the escalated radiation dose (\> 60 Gy) and the standard radiation dose (≤ 60 Gy) in GBM patients undergoing post-operative adjuvant therapy. Prognostic factors associated with the survival of GBM were also evaluated.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

We retrospectively reviewed the medical records of primary brain GBM patients in a medical center and its affiliated branch, both in Tainan, Taiwan. Patients with histology codes ICD-O-3 9440/3 in the cancer registry database who were diagnosed between 2005 and 2016 were identified. GBM variants of gliosarcoma, giant-cell, or epithelioid histologic differentiation were excluded. The inclusion criteria were older than 20 years of age, good performance status (ECOG less than 2), and undergoing curative brain irradiation. We excluded patients who had no pathologic confirmation or had received brain irradiation before the diagnosis of GBM. We extracted the following information from the database: age, sex, histology, extents of surgery, radiation dose, prescription of chemotherapy, and the date of last follow-up. The follow-up time was from the date of GBM diagnosis to October 2018.

The extent of surgery was assessed by both post-operative imaging and operation records. All the brain images were reviewed by an oncologist and a radiologist to confirm the size and location of the brain lesion. All patients received radiation using the technique of intensity-modulated radiation therapy (IMRT). The radiation dose 45--46 Gy was prescribed in 1.8--2.0 Gy daily fractions to the first planning target volume (PTV), which was defined as the gross tumor volume (GTV) plus perifocal edema for possible microscopic extension. The clinical target volume (CTV) was defined as GTV plus a 1.5--2.0 cm margin for microscopic extension, and the anatomical structure was considered. Then a subsequent boost of 15--20 Gy was given to GTV plus a 0.5--1.0 cm margin. The dose of the boost was determined on the basis of the physician's consideration. All patients were followed up with brain images and clinical visits regularly after therapy.

Literature search strategy {#sec004}
--------------------------

Literature search was conducted in December, 2019. We searched PubMed (National Library of Medicine) between January 1995 and December 2019 using "glioblastoma" or "brain tumor," "dose escalation" or "higher dose," and "radiation" or "radiotherapy" as key words. We included human studies published in full-text English. Because we were interested in understanding the clinical studies of escalated radiation, articles were not reviewed if they were case reports, animal studies, reports of radiation secondary to other conditions, or reports of surgical or radiological management of GBMs.

Statistical analysis {#sec005}
--------------------

OS and progression-free survival (PFS) were assessed in both groups. OS censored patients at death or the date of last follow-up, and PFS ended at locoregional recurrence or death from any cause. We applied Kaplan-Meier analyses for comparisons of survival and evaluated differences between the survival curves by the log-rank test. Differences in continuous variables were evaluated by the student *t* test or Wilcoxon rank sum test, and those in categorical variables were evaluated by the Fisher's exact test. To identify independent factors for survival, Cox proportional hazards model that included factors with *p* values smaller than 0.10 in the univariate analyses were constructed. In order to have better identification of survival factors, we further adopt Cox regression models with least absolute shrinkage and selection operator (LASSO) approach to establish the final model on the basis of Akaike information criterion with a correction (AICC) for small sample size \[[@pone.0233188.ref013]--[@pone.0233188.ref014]\]. Hazard ratios (HRs) and associated 95% confidence intervals (CIs) were calculated. A two-tailed *p* value \< 0.05 was considered statistically significant. All analyses were conducted by SPSS 24 for Windows (IBM, Armonk, NY, USA). SAS 9.4 for Windows software (SAS Institute, Cary, NC, USA) was used to apply the LASSO approach, with the SAS syntax PROC HPGENSELECT.

Ethics statement {#sec006}
----------------

The retrospective analysis was approved by the Chi Mei Medical Center institutional review board (IRB) and ethics committee (IRB number: 10710-L05 and 10810-L05). All the methods were carried out in accordance with the approved guideline, and all data were fully anonymized before accessed. Written informed consent of the patients or their families was not judged necessary for this kind of retrospective study by the Chi Mei Medical Center IRB.

Results {#sec007}
=======

From 2005 through 2016, 142 GBM newly diagnosed patients were identified in our database of cancer registry, and 84 of them fit in inclusion criteria. Of the 58 ineligible GBM patients, 52 did not undergo radiotherapy, 4 received palliative brain irradiation (\< 50 Gy), and 2 were younger than 20 years old. The patient's age at diagnosis ranged from 21 to 84 years old (median: 61 years) ([Table 1](#pone.0233188.t001){ref-type="table"}). Of the 84 patients, 52 (62%) were males, and 27 (32%) were diagnosed before 2010. Most (63, 75%) of the patients underwent subtotal or GTR, and 69 (82%) received chemotherapy. Among the patients who received chemotherapy, 46 (67% of the total) were prescribed with a TMZ-based regimen. The radiation dose ranged from 50.0 Gy to 66.6 Gy with a median of 60.0 Gy. While 15 (18%) patients received dose escalation boost \> 60.0 Gy with a median of 66 Gy (range: 61.2 to 66.6 Gy), only 4 patients did not reach the full 66-Gy boost dose, but no explicit medical records could be obtained. The irradiation volume ranged from 56 to 817 mL (median: 247 mL). The median OS of all enrolled patients was 14.0 months, while the median PFS was only 9.0 months.

10.1371/journal.pone.0233188.t001

###### Patient characteristics of glioblastoma.

![](pone.0233188.t001){#pone.0233188.t001g}

  Characteristics                                                               Patients (N = 84) (n, %)
  ----------------------------------------------------------------------------- --------------------------
  Age (year) (median, range)                                                    61 (2--84)
  Overall survival (month) (median, range)                                      14.0 (2.5--109.8)
  Progression-free survival (month) (median, range)                             9.0 (1.4--61.4)
  Sex                                                                           
   Male                                                                         52 (62)
   Female                                                                       32 (38)
  Operation[^a^](#t001fn001){ref-type="table-fn"}                               
   Yes                                                                          63 (75)
   Biopsy                                                                       21 (25)
  Radiation dose (Gy) (mean, range)                                             60.0 (50.0--66.6)
   \> 60                                                                        15 (18)
   ≤ 60                                                                         69 (82)
  Radiation volume (mL) (median, range)[^b^](#t001fn002){ref-type="table-fn"}   247 (56--817)
  Chemotherapy                                                                  
   Yes                                                                          69 (82)
   No                                                                           15 (18)
  Temozolomide-based regimen                                                    
   Yes                                                                          46 (67)
   Non-temozolomide regimen                                                     23 (33)
  Year of diagnosis                                                             
   2005--2010                                                                   27 (32)
   2010--2016                                                                   57 (68)

^a^Subtotal or gross-total resection, other than biopsy only.

^b^27 patients did not have detailed radiation volume.

The 15 patients with dose-escalation (\> 60 Gy) (escalated group) were younger than the 69 patients who received the standard 60-Gy dose (reference group) (median, 52 *vs*. 62 years old, *p* = 0.05), but the differences in age, sex, surgery, and chemotherapy did not reach statistical significance ([Table 2](#pone.0233188.t002){ref-type="table"}). The median radiation treatment volume was similar in both groups (249 ml in dose escalation *vs*. 247 ml in standard dose). Following age stratification at 70 years, we found patients older than 70 years seemed to be more likely to receive the standard dose, but the difference did not reach statistical significance (26% *vs*. 7%, *p* = 0.17). Following stratification by the year of diagnosis, we found a higher percentage of patients were assigned to receive the escalated dose before 2010 (73% vs. 27%, *p* \<0.01).

10.1371/journal.pone.0233188.t002

###### Comparison of glioblastoma patients treated with dose escalation (\> 60 Gy) and standard dose (≤ 60 Gy).
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                               Escalation\         Standard (N, %)    *p* value[^a^](#t002fn001){ref-type="table-fn"}
                                                                                (N, %)                                 
  ----------------------------------------------------------------------------- ------------------- ------------------ -------------------------------------------------
  Patients number                                                               15                  69                 

  Overall survival (month) (median, range)                                      33.8 (6.2--109.8)   12.5 (2.5--77.2)   \< 0.001

  Progression-free survival (month) (median, range)                             15.4 (13.1--61.4)   7.7 (1.4--55.0)    0.01

  Age (years) (median, range)                                                   52 (29--77)         62 (21--84)        0.05

  Age group (year)                                                                                                     0.17

   \> 70                                                                        1 (7)               18 (26)            

   ≤ 70                                                                         14 (93)             51 (74)            

  Sex                                                                                                                  0.24

   Male                                                                         7 (47)              45 (65)            

   Female                                                                       8 (53)              24 (35)            

  Surgery[^b^](#t002fn002){ref-type="table-fn"}                                                                        0.51

   Yes                                                                          10 (67)             53 (77)            

   Biopsy                                                                       5 (33)              16 (23)            

  Chemotherapy                                                                                                         0.73

   Yes                                                                          12 (80)             57 (83)            

   No                                                                           3 (20)              12 (17)            

  Temozolomide-based regimen[^c^](#t002fn003){ref-type="table-fn"}                                                     0.20

   Yes                                                                          5 (56)              41 (69)            

   Non-temozolomide regimen                                                     4 (44)              13 (31)            

  Year of diagnosis                                                                                                    \<0.01

   2005--2010                                                                   11 (73)             16 (23)            

   2010--2016                                                                   4 (27)              53 (78)            

  Radiation volume (mL) (median, range)[^d^](#t002fn004){ref-type="table-fn"}   247 (94--817)       249 (56--731)      0.66
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^*p* value for student t test, Wilcoxon rank sum test or Fisher's exact test.

^b^Subtotal or gross-total resection, other than biopsy only.

^c^6 patients did not have detailed records of chemotherapy regimen.

^d^27 patients did not have detailed records of radiation volume.

The escalated group had a better PFS than the reference group, with a median of 15.4 (range: 13.1--61.4) *vs*. 7.9 (range: 1.4--55) months (*p* = 0.01 for log-rank test) ([Fig 1](#pone.0233188.g001){ref-type="fig"}). In addition, the escalated group survived longer, with a median OS of 33.8 months (range: 6.2--109.8) *vs*. 12.5 (range: 2.5--77.2) months (p \< 0.01 for log-rank test) ([Fig 2](#pone.0233188.g002){ref-type="fig"}).

![Kaplan-Meier estimates of progression-free survival comparing glioblastoma patients receiving the standard dose (≤60 Gy) and those receiving dose escalation (\> 60 Gy).](pone.0233188.g001){#pone.0233188.g001}

![Kaplan-Meier estimates of overall survival comparing glioblastoma patients receiving a standard dose (≤60 Gy) and those receiving dose escalation (\> 60 Gy).](pone.0233188.g002){#pone.0233188.g002}

A univariate analysis to identify the factors affecting PFS found significant association of PFS with the escalated dose (HR = 0.42, 95%CI: 0.20--1.00) and age (\> 70 years: HR = 1.94, 95%CI: 1.07--3.52). In the multivariate analysis, only the escalated dose was identified as a significant predictor for prognosis (HR = 0.48, 95%CI: 0.23--0.98). Using LASSO approach, we found age \> 70 (HR = 1.55) and diagnosis year after 2010 (HR = 1.42) were unfavorable predictors of PFS, whereas a larger radiation volume (≥ 250 ml; HR = 0.81) was a favorable predictor ([Table 3](#pone.0233188.t003){ref-type="table"}).

10.1371/journal.pone.0233188.t003

###### Univariate and multivariate Cox regression analyses of progression-free survival for glioblastomas.
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                                                           Univariate                  Multivariate[^a^](#t003fn002){ref-type="table-fn"}          Multivariate[^b^](#t003fn003){ref-type="table-fn"}   
  -------------------------------------------------------- ------------------- ------- ---------------------------------------------------- ------ ---------------------------------------------------- ------
  Age group                                                                                                                                                                                             
   ≤ 70                                                    (reference)                                                                                                                                  
   \> 70                                                   1.94 (1.07--3.52)   0.03    1.64 (0.90--3.00)                                    0.11   1.55(0.78--3.09)                                     0.21
  Sex                                                                                                                                                                                                   
   female                                                  (reference)                                                                                                                                  
   Male                                                    1.17 (0.73--1.89)   0.63    NA                                                                                                               
  Radiation dose                                                                                                                                                                                        
   ≤ 60 Gy                                                 (reference)                                                                                                                                  
   \> 60 Gy                                                0.42 (0.22--0.81)   0.01    0.48 (0.23--0.98)                                    0.04                                                        
  Radiation volume[^b^](#t003fn003){ref-type="table-fn"}                                                                                                                                                
   \< 250ml                                                (reference)                                                                                                                                  
   ≥ 250ml                                                 0.78 (0.46--1.34)   0.38    NA                                                          0.81(0.45--1.39)                                     0.44
  Surgery[^c^](#t003fn004){ref-type="table-fn"}                                                                                                                                                         
   No                                                      (reference)                                                                                                                                  
   Biopsy                                                  0.91 (0.54--1.54)   0.74    NA                                                                                                               
  Chemotherapy                                                                                                                                                                                          
   No                                                      (reference)                                                                                                                                  
   Yes                                                     0.86 (0.43--1.73)   0.67    NA                                                                                                               
  Year of diagnosis                                                                                                                                                                                     
   2005--2010                                              (reference)                                                                                                                                  
   2010--2016                                              1.51 (0.93--2.47)   0.098   1.09 (0.64--1.86)                                    0.75   1.42(0.73--2.76)                                     0.30

HR, hazard ratio; CI, confidence interval, NA: not available (not included in the model).

^a^*p* value \<0.10 were included in multivariable analysis.

^b^Variables were selected using LASSO method in multivariate analysis.

^c^27 patients did not have detailed radiation volume.

^d^Subtotal or gross-total resection, other than biopsy only.

Univariate analyses showed only two factors were significant predictors of OS. The escalated group had a better OS (HR = 0.34, 95%CI: 0.18--0.64), and those who were diagnosed after 2010 had a worse OS (HR = 2.01, 95%CI: 1.12--3.32). The other variables did not have HRs with a p value \< 0.10, including age stratification, sex, surgery, chemotherapy, and radiation volume. Further, when the two significant factors (year of diagnosis and radiation dose) were put into the multivariate Cox proportional hazard model, only the escalated dose was identified as an independent predictor for prognosis (HR = 0.40, 95%CI: 0.21--0.78). In addition, the LASSO method selected diagnosis year, radiation volume, and radiation dose into the final model. We also found the escalated dose (HR = 0.47) and a larger radiation volume (HR = 0.76) were predictors for better OS ([Table 4](#pone.0233188.t004){ref-type="table"}). The final model of LASSO based on the criteria of AICC was listed in [S1 Table](#pone.0233188.s001){ref-type="supplementary-material"}. Following detailed statistical analysis, a moderate radiation dose escalation (\> 60 Gy) was found as an independent factor affecting OS in GBM patients.

10.1371/journal.pone.0233188.t004

###### Univariate and multivariate Cox regression analyses of overall survival for glioblastomas.
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                                                               Univariate                     Multivariate[^a^](#t004fn002){ref-type="table-fn"}           Multivariate[^b^](#t004fn003){ref-type="table-fn"}   
  ------------------------------------------------------------ ------------------- ---------- ---------------------------------------------------- ------- ---------------------------------------------------- ------
  Age group                                                                                                                                                                                                     
   ≤ 70                                                        (reference)                                                                                                                                      
   \>70                                                        1.29 (0.76--2.20)   0.35       NA                                                                                                                
  Sex                                                                                                                                                                                                           
   female                                                      (reference)                                                                                                                                      
   Male                                                        1.18 (0.74--1.86)   0.49       NA                                                                                                                
  Radiation dose                                                                                                                                                                                                
   ≤ 60 Gy                                                     (reference)                                                                                                                                      
   \> 60 Gy                                                    0.34 (0.18--0.64)   \< 0.001   0.40 (0.21--0.78)                                    0.007   0.47(0.17--1.35)                                     0.16
  Radiation volume[^b^](#t004fn003){ref-type="table-fn"}                                                                                                                                                        
   \< 250 mL                                                   (reference)                                                                                                                                      
   ≥ 250 mL                                                    0.75 (0.42--1.31)   0.30       NA                                                           0.76(0.43--1.34)                                     0.34
  Surgery                                                                                                                                                                                                       
   No                                                          (reference)                                                                                                                                      
   Yes                                                         0.93 (0.55--1.58)   0.78       NA                                                                                                                
  Chemotherapy                                                                                                                                                                                                  
   No                                                          (reference)                                                                                                                                      
   Yes                                                         0.77 (0.43--1.38)   0.37       NA                                                                                                                
  Chemotherapy regimen[^e^](#t004fn006){ref-type="table-fn"}                                                                                                                                                    
  No chemotherapy                                              (reference)                                                                                                                                      
  TMZ-based                                                    0.56 (0.30--1.08)                                                                                                                                
  Non-TMZ                                                      0.54 (0.18--1.60)   0.21       NA                                                                                                                
  Year of diagnosis                                                                                                                                                                                             
   2005--2010                                                  (reference)                                                                                                                                      
   2010--2016                                                  2.01 (1.12--3.32)   0.006      1.52 (0.9--2.57)                                     0.12    1.98(0.98--4.02)                                     0.06

HR, hazard ratio; CI, confidence interval; NA: not available (not included in the model); TMZ, temozolomide.

^a^*p* value \< 0.10 were included in multivariable analysis.

^b^Variables were selected using LASSO method in multivariate analysis.

^c^27 patients did not have detailed radiation volume.

^d^Subtotal or gross-total resection, other than biopsy only.

^e^6 patients did not have detailed records of chemotherapy regimen.

Discussion {#sec008}
==========

GBM is the deadliest primary malignant brain tumor, typically presenting as a single brain tumor and tending to recur locally just adjacent to the primary tumor site. Despite improvements in imaging, surgery, radiotherapy, and chemotherapy, the majority of GBM patients continue to recur at the site of the original tumor site. According to previous studies on the pattern of failure for GBM patients, more than 80% of tumors recurred within 2 cm of the pre-surgical tumor margin. Local tumor progression or relapse within or adjacent to the original brain lesion occurs in approximately 90% of GBM patients \[[@pone.0233188.ref003]--[@pone.0233188.ref005]\]. Therefore, local control is most paramount to improving the GBM outcomes. There are many clinical studies on the extent of surgery and escalated radiation dose to prevent local recurrence. However, clinical circumstances are often associated with difficulties in achieving a GTR, such as old age, comorbidities, performance status, large tumor size, and multiple lesions \[[@pone.0233188.ref004], [@pone.0233188.ref006], [@pone.0233188.ref015]--[@pone.0233188.ref017]\].

A pooled analysis of six randomized trials of radiotherapy versus no radiotherapy following surgery reported significant survival benefits in the cohort of radiotherapy \[[@pone.0233188.ref018], [@pone.0233188.ref019]\]. However, the survival following standard 60-Gy radiation was poor, and OS remained dismal without long-term survivors. Therefore, prescribing a higher radiation dose for GBM has been attempted in many clinical studies, including altered fractionation, stereotactic radiosurgery, and brachytherapy to deliver a higher dose to the PTV region with the hope of improving local tumor control \[[@pone.0233188.ref005], [@pone.0233188.ref008]--[@pone.0233188.ref010]\]. A clear dose-response relationship has not been identified for GBM. However, our study supports the survival benefit of GBM using the IMRT technique to deliver a moderately escalated dose (\> 60-Gy) with conventional 1.8--2.0 Gy daily fractionation in contrast to standard 60-Gy regimen only. Our finding is well in line with a dose escalation study of Zschaeck et al \[[@pone.0233188.ref011]\] with 133 patients receiving standard 60-Gy radiotherapy and 23 receiving moderate dose escalation (66-Gy), which found the higher dose lead to decreased intracranial recurrence, i.e. better OS. Zhong et al. also reported improved PFS and OS following a moderately integrated radiation boost scheme (64 Gy over 27 fractions to GTV) in GBM patients \[[@pone.0233188.ref012]\]. In a study by Graf et al., the median survival time was 3.0 months for a radiation dose of 55 Gy or less, 8.6 months for doses between 56 and 65 Gy, and 9.6 months for a dose range between 66 and 75 Gy (*p* \< 0.01) \[[@pone.0233188.ref020]\]. Two other studies using historical data also showed a survival benefit in patients who received a higher radiation dose \[[@pone.0233188.ref021], [@pone.0233188.ref022]\].

On the contrary, the RTOG 98--03 study recruited GBM patients to receive four escalated radiation dosages (66, 72, 78, and 84 Gy) and found no survival benefits among groups with dose escalation. However, the results concluded the feasibility of delivering dosages higher than the standard 60 Gy with an acceptable toxicity of late brain necrosis \[[@pone.0233188.ref009]\]. Nakagawa et al. reported a trial of dose escalation up to 90 Gy and found those receiving such a high dose had a lower rate of local recurrence, whereas the OS was similar to the conventional dose group, though this study concluded that the benefit of a higher dose was not clear \[[@pone.0233188.ref010]\]. Additional reports have indicated that an escalated dose beyond 60 Gy for GBM did not improve OS \[[@pone.0233188.ref005], [@pone.0233188.ref009], [@pone.0233188.ref010], [@pone.0233188.ref023]\]. To conclude, the National Comprehensive Cancer Network still considered 60-Gy radiotherapy as the standard of care. However, the debate of the pros and cons of an escalated radiation dose in GBM have continued. While the optimal method for delivering post-operative dose or methods of radiation remains unclear, NGR BN-001 conducted a phase II trial study to compare hypofractionated dose-escalated photon or proton beam radiation therapy with standard-dose radiation therapy to evaluate dose escalation for GBM patients. As a result of effort to summarize the findings in previous studies, we conducted a literature review to identify the relationship between escalation and outcome. Databases of Medline and PubMed were searched. Clinical cases series and Radiation Therapy and Oncology Group reports are listed in [Table 5](#pone.0233188.t005){ref-type="table"}.

10.1371/journal.pone.0233188.t005

###### Literature review on the escalated radiation dose trial of glioblastoma.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study \[reference\]                                  Escalated radiation dose trial                    N             Median survival (month)   Concurrent chemotherapy   Survival benefit
  ---------------------------------------------------- ------------------------------------------------- ------------- ------------------------- ------------------------- ------------------
  Nakagawa *et al*. (1998)\[[@pone.0233188.ref010]\]   Low dose (60--80Gy)                               21            17                        Nimustine, vincristine    No

  High dose (90 Gy)                                    17                                                                                                                  

  RTOG 98-03(2002) \[[@pone.0233188.ref009]\]          PTV\< 75 cm3 46 Gy in 23 fractions + 20--38 Gy\   94            11.6 (66 Gy)              BCNU                      No
                                                       (3DCRT)                                                                                                             

  11.8 (72 Gy)                                                                                                                                                             

  11.8 (78 Gy)                                                                                                                                                             

  19.3 (84 Gy)                                                                                                                                                             

  PTV≥ 75 cm3 46 Gy in 23 fractions + 20--38 Gy\       109                                               8.2 (66 Gy)                                                       
  (3DCRT)                                                                                                                                                                  

  6.5 (72 Gy)                                                                                                                                                              

  6.9 (78 Gy)                                                                                                                                                              

  6.0 (84 Gy                                                                                                                                                               

  Chan *et al*. (2002) \[[@pone.0233188.ref005]\]      60 Gy + 10 Gy (3DCRT)                             20            13.9                      No                        No

  60 Gy + 20 Gy                                        55                                                12.9                                                              

  60 Gy + 30 Gy                                        34                                                11.7                                                              

  RTOG 93-05(2004)\[[@pone.0233188.ref023]\]           60 Gy in 30 fractions                             97            13.6                      BCNU                      No

  60 Gy + 15--24 Gy (stereostatic radiosurgery)        89                                                13.5                                                              

  Graf *et al*. (2005) \[[@pone.0233188.ref020]\]      56-65Gy                                           83            8.6                       No                        Yes

  66-75Gy                                              52                                                9.6                                                               

  Tsien *et al*. (2012)\[[@pone.0233188.ref022]\]      66---81Gy                                         38            20.1                      TMZ                       Yes

  Zschaeck *et al*. (2018)\[[@pone.0233188.ref011]\]   60Gy                                              133           15.3                      TMZ                       Yes

  66Gy                                                 23                                                18.8                                                              

  Kim *et al*. (2019) \[[@pone.0233188.ref021]\]       66-81Gy                                           82            18.7                      TMZ                       Yes

  Zhong et al. (2019) \[[@pone.0233188.ref012]\]       64 Gy in 27 fractions (SIB)                       80            21                        TMZ                       Yes

  Current study                                        60 Gy in 30--33 fractions                         69            12.5                      TMZ                       Yes

  \>60 Gy (conventional boost)                         15                                                33.8                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RTOG, radiation therapy and oncology group; SIB, simultaneous integrated boost; 3D CRT, 3D conformal radiotherapy; TMZ: temozolomi

It is well-known that achieving GTR is crucial in the management in GBM. However, GBM is a diffusely infiltrative brain tumor, where tumor cells often extend beyond the maximum resection. Therefore, GTR only should be regarded as a debulking operation, and, in the most clinical scenarios, extensive radical surgery is not feasible. Kreth et al. reported only about 50% of patients could receive GTR and those that did had better survival \[[@pone.0233188.ref016]\]. Awad et al. found OS significantly improved with the extent of resection in a univariate analysis, averaging 22, 19, and 13 months for \> 90%, 80--90%, and 70--80% tumor resection, respectively. However, after multivariate analysis, the extent of resection no longer correlated with OS \[[@pone.0233188.ref024]\]. Our study only differentiated between tumor resection and biopsy-only from hospital database analysis and found no significant association between resection and survival. Nonetheless, radical surgery should be weighted between the clinical recovery and the risk of neurologic deficit. Although we failed to demonstrate the benefits of the extent of resection in our cohort, we believe the extent of resection is imperative in GBM. Studies supported the resection of more contrast-enhancing portion of a GBM leads to increased survival. Additional resection of the T2-weighted MRI region appears to confer an added survival advantage \[[@pone.0233188.ref024]--[@pone.0233188.ref026]\]. Radiation volume should be highly correlated with the extent of tumor resection. In our study, the median radiation treatment volume was similar between the two groups (249 ml in dose escalation *vs*. 247 ml in standard dose). A larger radiation volume (≥ 250 ml) did not yield better OS and PFS in the univariate analysis. However, the LASSO selector identified radiation volume ≥ 250ml as a favorable predictor for PFS (HR = 0.81) and OS (HR = 0.76) as well.

We analyzed several prognostic variables including age, sex, and chemotherapy. The date of diagnosis before 2010 was a significant factor for worse OS in the univariate analysis. However, after adjusting for radiation dose, it was no longer significant in the OS multivariate analysis. Whereas diagnosis year before 2010 was not associated with OS or PFS in proportional hazards model, when we conducted Cox models with a LASSO selector, it was included in the models for both OS and PFS, signifying diagnosis year might be a confounding factor. The number of GBM patients assigned to accept dose escalation with conventional boost had decreased after 2010 at our hospitals. The rationale for opting for standard 60-Gy, derived from the concern that either dose intensification may come with a cost, or dose intensification has involved utilizing various techniques, such as hypofractionated or simultaneous integrated boost dose, and/or stereotactic radiosurgery boost \[[@pone.0233188.ref025]\].

The age of the cohort in the escalated dose group was younger than the cohort in the standard group in our study. Younger age is significantly associated with better survival in GBM patients in the literature \[[@pone.0233188.ref026], [@pone.0233188.ref027]\]. Again, Cox models with a LASSO selector identified age as a potential confounding factor on survival in our study which could impact the results. Evidence-based clinical practice guidelines recommend patients older than 70 years old consider hypofractionated radiotherapy \[[@pone.0233188.ref028]\]. So, we used 70 years as a cutoff and found the age \> 70 group had a worse PFS in the univariate analysis. However, after adjusting for the radiation dose in multivariate analysis, it was no longer a significant predictor for PFS. Roa et al. randomly assigned GBM patients aged 60 years or older to receive either a standard course (60 Gy in 30 fractions over 6 weeks) or a shorter course (40 Gy in 15 fractions over 3 weeks) of radiation after surgery and found no differences in survival between the two groups \[[@pone.0233188.ref028]\], which is compatible to our finding.

Currently, GBM patients receive adjuvant TMZ as the standard chemotherapy regimen. Nonetheless, only 46% of our patients received TMZ regimen, and chemotherapy dose and regimen did not conform to the standards in our study. The reason was that TMZ was not fully reimbursed by the National Health Insurance in Taiwan in the early 2000s. Therefore, patients were treated with various chemotherapy regimens, like BCNU and cisplatin. Non-uniform chemotherapy might mask the significance of chemotherapy in our study.

The 2016 WHO classification of central nervous tumors introduced molecular parameters in addition to histology to define GBM tumor entities \[[@pone.0233188.ref029]\]. However, we enrolled GBM patients between 2005 and 2016, and IDH and MGMT markers were not mandatory for routine pathologic reports. Because of the lack of data, we were unable to evaluate the prognostic significance of these molecular markers in our study.

Conclusions {#sec009}
===========

Although the current study was limited by its retrospective design, the escalated dose (\> 60-Gy) with similar treatment volumes resulted in survival benefit after adjusting for other prognostic variables. Dose escalation was still identified as an independent factor for OS by using Cox models with a LASSO selector. The limitations of this study include non-uniform chemotherapeutic treatment, longer accrual of patients, younger age in the high dose group, and those along with the general restrictions of a retrospective analysis. In addition, the small cohort and relatively large number of factors of interest limited the potential for multiple comparisons and the evaluation of certain factors, such as completeness of resection. Moreover, the molecular characteristics, such as MGMT or IDH mutation status, were not routinely assessed in the cohort.
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Response to Reviewers' Comments

First, we feel very happy to receive substantive and excellent comments from reviewers. We respond the comments line by line accordingly. The revised manuscript was marked in red in corrected words, paragraphs, and sections.

Comments from Reviewer 1：

1\. While the authors acknowledge the lack of molecular characterization, the absence of capturing/adjusting for IDH/MGMT severely limits interpretation of clinical outcomes in a small cohort. If at all possible I would encourage the authors to adjust for either of the above even if many values are missing.

Response:

The 2016 WHO classification of central nervous tumors has introduced molecular parameters in addition to histology to define GBM tumor entities. However, we enrolled GBM patients between 2005 and 2016, and so the markers of IDH mutation and MGMT were not mandatory in routine pathologic reports. Actually, in our cohort, we could not find any one who had been checked for the status of MGMT. In response to the Reviewer's comment, we changed the last sentence of Discussion to "Because of the lack of data, we were unable to evaluate the prognostic significance of these molecular markers in our study." in the revised manuscript. We have also added this as a limitation to Discussion and Conclusion in the revised manuscript.

2\. I would encourage the authors to consider using statistical modeling such as penalized Cox models with a LASSO selector given the small cohort and relatively large number of factors of interest. More robust methodology would further limit the potential for multiple comparison error.

Response:

According to the Reviewer's suggestion, we performed the analysis and added the results of LASSO approach in Table 3, Table 4, and Supplement Table 1. Following detailed statistical analysis, a moderate radiation dose escalation (\> 60 Gy) was still identified as an independent factor affecting OS in GBM patients. In addition, we have added related description to the Abstract and main text in the revised manuscript.

3\. Rather than adjusting for chemotherapy/non-chemotherapy, I would encourage the authors to adjust for temozolomide/non-tmz chemo/none given the substantial improvement with TMZ in MGMT methylated patients (perhaps to some extent in unmethylated patients as well given the potential for protein expression despite methylation status).

Response:

Among the 69 (82%) patients who received chemotherapy, only 46 (67% of the total) were prescribed with a TMZ-based regimen. In response to the Reviewer's comments, we have tried to make comparison among three groups, namely temozolomide chemotherapy, non-TMZ chemotherapy, and no chemotherapy, but found no significant differences regarding overall survival (OS). We have added the result in Table 4.The results are shown in following table:

Univariable (OS)

Variable HR (95% CI) p-value

No chemotherapy (reference) 0.211

TMZ-based regimen 0.56(0.30-1.08)

Non-TMZ Chemotherapy 0.54(0.18-1.60)

4\. Would recommend the authors mention NRG-BN-001 which is investigating dose-escalated RT for patients with GBM in the era of TMZ.

Response:

According to the Reviewer's suggestion, we have added related information to Discussion in the revised manuscript.

5\. It is a little concerning to me outcomes were worse for patients diagnosed after 2010. Given multiple large database analyses have associated improved OS in more modern cohorts (PMID 27214765, 28452053) this finding to me highlights the potential presence of an unadjusted maldistribution of molecular mutations (IDH/MGMT) which may be modulating PFS/OS.

Response:

We can understand the Reviewer's concern that the survival became worse in patients who received treatment in recent years. Although we have no data to address the possible effects of IDH/MGMT, we believe it was quite likely attributable to dose escalation. Most of the patients who received the escalated dose were diagnosed before 2010, while most of those who received the standard dose were diagnosis after 2010. We have added related description to Discussion in the revised manuscript.

Comment from Reviewer 2：

This retrospective study evaluated the effect of radiation dose on survival outcomes for patients with glioblastoma and identified dose escalation as being associated with improved outcomes. The authors\' study adds to the literature regarding dose escalation. Since GBM frequently recurs locally, it is important to identify factors that correlate with local recurrence. Although the dose escalation group only included 15 patients, it is interesting that these patients did experience improved OS. Only one patient in this group was over the age of 70, while there were 18 patients over age 70 in the standard dose arm. Although age was found to not be associated with outcomes on multivariate analysis, it is probable that this would be significant with a larger sample size since age is so critical to GBM outcomes. One recommendation for the authors is to more clearly separate which patients underwent GTR or STR, since completeness of resection is also associated with improved outcomes in this patient population. Additionally, I recommend more clearly highlighting that there was no difference in treatment volume between the two arms. Overall, this is an interesting study, and although retrospective in nature with all the requisite caveats and without molecular data, it adds an important data point to GBM literature with respect to radiation dose.

Response:

We thank the Reviewer for the encouraging comment. While we agree that the completeness of resection is also associated with improved outcomes, because of the small case number, we would not have the statistical power to adjust for more variables. We added "the completeness of resection is also associated with improved outcomes, because of the small case number, we could not evaluate or adjust its effects in our study" as a limitation to both Discussion. As suggested by the Reviewer, we also added "but their treatment volumes were similar to the others" to the Abstract and "with similar treatment volumes" to the Discussion to highlight that there was no difference in treatment volume between the two arms.

Comment from Reviewer 3：

Overall the manuscript is logical and states its purpose. The subject is not original, but the data and the patients cohorts reported in the study are unique, thereby meeting one of the criteria for publishing in PLOS One. It would be good if there were more patients, and I would encourage the authors to see if they can combine patient cohorts with other centers, recognizing that this may not ultimately be possible. There are, however, many grammatical and work usage errors in the manuscript, and at a minimum these need to be corrected. I am scanning the manuscript with my copyedits in blue.

Response:

We agree with the Reviewer's suggestion that a multicenter study is a good idea to expand the database, but it is not achievable in a short period time. We believe the publication of this manuscript will provide a more solid ground to call for such a study. We really appreciate the editing of the manuscript and have corrected those and other errors in the manuscript.
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